Capital Research Global Investors Purchases 4,611 Shares of Cencora, Inc. (NYSE:COR)

Capital Research Global Investors raised its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 0.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,899,450 shares of the company's stock after purchasing an additional 4,611 shares during the period. Capital Research Global Investors owned approximately 1.50% of Cencora worth $651,448,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC grew its position in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Cencora in the 4th quarter worth approximately $30,000. Kentucky Trust Co bought a new position in shares of Cencora in the fourth quarter valued at approximately $33,000. Householder Group Estate & Retirement Specialist LLC increased its position in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co lifted its holdings in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

COR has been the subject of several research analyst reports. Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Wells Fargo & Company upped their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. JPMorgan Chase & Co. lifted their price objective on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, Morgan Stanley set a $288.00 price objective on shares of Cencora in a report on Tuesday, April 15th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Cencora has a consensus rating of "Moderate Buy" and an average price target of $284.55.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares in the company, valued at $89,027,442.53. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,223 shares of company stock worth $13,580,967. Company insiders own 10.80% of the company's stock.

Cencora Trading Up 0.4 %

NYSE:COR traded up $1.24 during trading hours on Friday, reaching $283.63. The company's stock had a trading volume of 853,264 shares, compared to its average volume of 1,514,355. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a market capitalization of $55.00 billion, a price-to-earnings ratio of 40.34, a PEG ratio of 1.31 and a beta of 0.55. The firm has a 50-day simple moving average of $267.20 and a 200-day simple moving average of $248.71. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $296.65.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.78%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio (DPR) is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.